Regenxbio Inc (RGNX) Stock Price, Quote & News

Company Profile

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phas...

Industry: Biotechnology

Sector: Healthcare

Phone: 240 552 8181

Website: www.regenxbio.com

Address:

9804 Medical Center Drive, Rockville, United States

They_call_me_tater_salad Aug. 22 at 5:56 PM

$RGNX In this morning for 20k shares at $8.34. Will be riding this one through PDUFA in Feb.

0 · Reply

Stock1701 Aug. 21 at 3:13 PM

$RGNX Started a position with a 1k shares. Will add more on any dips. High Insti. Ownership and should have some good data in Sept.

1 · Reply

maphere Aug. 20 at 8:32 PM

$CLSD $OCUL $EYPT $RGNX July 31,2025 The Retina Radar With Dr. Arshad Khanani: Sustained Delivery With Dr. David Almeida Start at 12:00, pay attention at 16:00 and 20:50 https://ophthalmology.libsyn.com/the-retina-radar-with-dr-arshad-khanani-sustained-delivery-with-dr-david-almeida

1 · Reply

WaveRB77 Aug. 19 at 10:38 PM

$RGNX BLAME Sarepta drug ELEVIDYS.After approval had 3 deaths.FDA will be more diligent.

0 · Reply

metalcook Aug. 19 at 6:13 PM

$RGNX does this delay mean no more priority voucher as approval DNLI is planned in Jan 2026...

3 · Reply

BRITLS Aug. 19 at 2:17 PM

$RGNX such a game played here

0 · Reply

JarvisFlow Aug. 19 at 11:00 AM

HC Wainwright & Co. has adjusted their stance on Regenxbio ( $RGNX ), setting the rating to Buy with a target price of 34.

0 · Reply

DCRMIA Aug. 19 at 10:51 AM

$RGNX "Stifel maintains Regenxbio Inc at ’buy’ with a price target of $40.00" https://www.investing.com/news/pro/stifel-maintains-regenxbio-inc-at-buy-with-a-price-target-of-4000-4199654

0 · Reply

rando321456 Aug. 19 at 10:41 AM

$RGNX Abit odd out of the FDA will be interesting if they get some pressure out of the MPS II community to get the drug through faster. Outside of our financial interest as investors in theory any delay in treatment with this drug is quite costly to the children who suffer this disease.

2 · Reply

lebranjames Aug. 18 at 11:15 PM

$RGNX expect a big drop tomorrow, these delays typically don’t go over well. Time is money 💰

3 · Reply

FDA Extends Decision Date On Regenxbio's Gene Therapy Into Next Year

Aug 18, 2025, 5:00 PM EDT - 6 days ago

REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II

Aug 8, 2025, 9:11 AM EDT - 17 days ago

REGENXBIO Inc. (RGNX) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:05 AM EDT - 18 days ago

REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights

Aug 7, 2025, 7:00 AM EDT - 18 days ago

REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy

Jul 31, 2025, 7:05 AM EDT - 25 days ago

REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights

Jul 10, 2025, 11:54 AM EDT - 6 weeks ago

REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy

Jun 6, 2025, 4:02 PM EDT - 2 months ago

Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome

Jun 5, 2025, 11:43 AM EDT - 2 months ago

Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer

Jun 5, 2025, 7:05 AM EDT - 2 months ago

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

Jun 2, 2025, 7:05 AM EDT - 3 months ago

REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202

May 19, 2025, 4:05 PM EDT - 3 months ago

REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

May 14, 2025, 7:13 AM EDT - 3 months ago

FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment

May 13, 2025, 7:07 AM EDT - 3 months ago

REGENXBIO Inc. (RGNX) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:05 AM EDT - 3 months ago

REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II

May 12, 2025, 4:05 PM EDT - 3 months ago

REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights

May 8, 2025, 7:05 AM EDT - 3 months ago

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting

May 6, 2025, 7:05 AM EDT - 3 months ago

REGENXBIO to Participate in Upcoming Investor Conferences

Apr 30, 2025, 4:05 PM EDT - 4 months ago

REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights

Mar 26, 2025, 12:31 PM EDT - 5 months ago

5 Reasons To Buy Regenxbio Right Now

Mar 19, 2025, 9:15 AM EDT - 5 months ago

REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY

Mar 13, 2025, 6:44 PM EDT - 5 months ago

REGENXBIO Inc. (RGNX) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 4:05 PM EDT - 5 months ago

REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates

Mar 10, 2025, 7:05 AM EDT - 6 months ago

REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Mar 4, 2025, 7:31 AM EST - 6 months ago

REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases

Feb 26, 2025, 4:05 PM EST - 6 months ago

REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

Feb 11, 2025, 3:20 PM EST - 6 months ago

Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns

Jan 30, 2025, 7:05 AM EST - 7 months ago

REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025

Jan 16, 2025, 4:01 AM EST - 7 months ago

Regenxbio: Wet AMD ABBV-RGX-314 Results Remain On Track For 2026

AMD

Jan 15, 2025, 3:27 PM EST - 7 months ago

Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again

Jan 14, 2025, 5:00 AM EST - 7 months ago

REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases

Jan 13, 2025, 8:31 AM EST - 8 months ago

AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program

ABBV

Dec 6, 2024, 6:29 PM EST - 9 months ago

Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

AMTM APO CMA CRI CRS HPP KELYA

Nov 18, 2024, 7:05 AM EST - 10 months ago

REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA

Nov 14, 2024, 7:05 AM EST - 10 months ago

REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202

Nov 6, 2024, 11:16 PM EST - 10 months ago

REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:05 PM EST - 10 months ago

REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates

Oct 31, 2024, 3:38 PM EDT - 10 months ago

REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track

Oct 30, 2024, 7:05 AM EDT - 10 months ago

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights

Oct 21, 2024, 7:05 AM EDT - 11 months ago

REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024

Oct 18, 2024, 7:05 AM EDT - 11 months ago

REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting

Sep 23, 2024, 4:05 PM EDT - 11 months ago

REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference

Sep 17, 2024, 7:05 AM EDT - 1 year ago

REGENXBIO Appoints Mitchell Chan as Chief Financial Officer

Sep 3, 2024, 8:04 AM EDT - 1 year ago

REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect

Aug 27, 2024, 7:05 AM EDT - 1 year ago

REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

Aug 8, 2024, 7:05 AM EDT - 1 year ago

REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 6, 2024, 4:03 PM EDT - 1 year ago

Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder

Aug 1, 2024, 11:06 PM EDT - 1 year ago

REGENXBIO Inc. (RGNX) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 4:05 PM EDT - 1 year ago

REGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights

Aug 1, 2024, 7:03 AM EDT - 1 year ago

REGENXBIO ANNOUNCES NEW POSITIVE DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202

They_call_me_tater_salad Aug. 22 at 5:56 PM

$RGNX In this morning for 20k shares at $8.34. Will be riding this one through PDUFA in Feb.

0 · Reply

Stock1701 Aug. 21 at 3:13 PM

$RGNX Started a position with a 1k shares. Will add more on any dips. High Insti. Ownership and should have some good data in Sept.

1 · Reply

maphere Aug. 20 at 8:32 PM

1 · Reply

WaveRB77 Aug. 19 at 10:38 PM

$RGNX BLAME Sarepta drug ELEVIDYS.After approval had 3 deaths.FDA will be more diligent.

0 · Reply

metalcook Aug. 19 at 6:13 PM

$RGNX does this delay mean no more priority voucher as approval DNLI is planned in Jan 2026...

3 · Reply

BRITLS Aug. 19 at 2:17 PM

$RGNX such a game played here

0 · Reply

JarvisFlow Aug. 19 at 11:00 AM

HC Wainwright & Co. has adjusted their stance on Regenxbio ( $RGNX ), setting the rating to Buy with a target price of 34.

0 · Reply

DCRMIA Aug. 19 at 10:51 AM

$RGNX "Stifel maintains Regenxbio Inc at ’buy’ with a price target of $40.00" https://www.investing.com/news/pro/stifel-maintains-regenxbio-inc-at-buy-with-a-price-target-of-4000-4199654

0 · Reply

rando321456 Aug. 19 at 10:41 AM

2 · Reply

lebranjames Aug. 18 at 11:15 PM

$RGNX expect a big drop tomorrow, these delays typically don’t go over well. Time is money 💰

3 · Reply

ians Aug. 13 at 7:31 PM

$IOVA $IBRX $RGNX🚀 STRONG follow-thru from yesterday’s bounce. Run-up in progress 👍☘️💎

3 · Reply

PollyPo Aug. 13 at 6:07 PM

$RGNX why this price action?

0 · Reply

BRITLS Aug. 13 at 2:21 PM

$RGNX glad i bought the dip...lol

0 · Reply

BRITLS Aug. 11 at 5:40 PM

$RGNX hmm

1 · Reply

JarvisFlow Aug. 8 at 6:32 PM

RBC Capital has updated their rating for Regenxbio ( $RGNX ) to Outperform with a price target of 17.

1 · Reply

JarvisFlow Aug. 8 at 2:28 PM

Barclays has adjusted their stance on Regenxbio ( $RGNX ), setting the rating to Overweight with a target price of 50 → 37.

0 · Reply

WaveRB77 Aug. 8 at 1:36 PM

$RGNX never understand this stock.Any good news and the stock sinks.

0 · Reply

JarvisFlow Aug. 8 at 12:30 PM

Chardan Capital updates rating for Regenxbio ( $RGNX ) to Buy, target set at 52.

0 · Reply

rando321456 Aug. 7 at 9:45 PM

$CLSD $RGNX On SCS vs. Subretinal so given that there seems to be a pretty clear dose response over longer periods of time in this latest readout this raises a question for me. What are the volume limits for injection in the subretinal space vs. the suprachoroidal space? Is the suprachoroidal space potentially advantaged in terms of the dose size of gene therapy that can be delivered into it? Just looking at some of the numbers Regenx is putting about 10x the dose of their subretinal dose into the SCS. I do wonder if this dosing differential could lead to a fundamentally advantaged product profile vs even subretinal delivery.

1 · Reply

maphere Aug. 7 at 9:02 PM

$RGNX $RGNX $CLSD $OCUL $EYPT A recent survey at ASRS demonstrated a majority of Retinal Specialists excitement for upcoming treatments for Wet Amd is Gene therapy. TKIs did not rate as high which may be why CLSD did not get a finance deal for CLS-AX and makes me wonder if OCUL and EYPT are simply floating on hype. An n = 987 is not a small number. https://www.asrs.org/asrs-community/pat-survey/results-new/1078?evergreen=staff

5 · Reply

DCRMIA Aug. 7 at 4:51 PM

$RGNX "Nebius Group PT Raised to $75 at DA Davidson" https://www.investing.com/news/pro/raymond-james-maintains-regenxbio-inc-at-outperform-with-a-price-target-of-2900-4177718

0 · Reply

DarkOrb Aug. 7 at 4:23 PM

$RGNX Trading down today on DR delay and concern over ABBV partnership change? Waiting on @maphere 's always insightful views.

3 · Reply

Market Cap	455.13M
Revenue (ttm)	83.33M
Net Income (ttm)	-227.10M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-272.53%
Debt to Equity Ratio	0.00

Volume	1,355,200
Avg Vol	722,960
Day's Range	N/A - N/A
Shares Out	50.51M
Stochastic %K	86%
Beta	1.11
Analysts	Strong Sell
Price Target	$30.00